Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
Status:
Completed
Trial end date:
2020-11-18
Target enrollment:
Participant gender:
Summary
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin
vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention
strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban,
or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin.
The information gained will empower cancer patients and physicians to make more informed
choices about anticoagulation strategies to manage VTE.